Nuvectis Pharma
NVCT
82 hedge funds and large institutions have $189M invested in Nuvectis Pharma in 2026 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 34 increasing their positions, 11 reducing their positions, and 6 closing their positions.
4,367% more capital inflows, than outflows
Capital inflows: $65.3M | Capital outflows: $1.46M
938% more call options, than puts
Call options by funds: $13.6M | Put options by funds: $1.31M
367% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 6
209% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 11
32% more funds holding
Funds holding: 62 → 82 (+20)
21.4% more ownership
Funds ownership: 16.97% → 38.36% (+21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tang Capital Management
San Diego,
California
|
+$17.4M |
| 2 |
Perceptive Advisors
New York
|
+$11.2M |
| 3 |
Soleus Capital Management
Greenwich,
Connecticut
|
+$11.2M |
| 4 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.29M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Occam Crest Management
Darien,
Connecticut
|
-$560K |
| 2 |
Goldman Sachs
New York
|
-$231K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$226K |
| 4 |
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$117K |
| 5 |
Nations Financial Group
Cedar Rapids,
Iowa
|
-$100K |
NVCT Hedge Fund Activity: Q2 2026 in Review
82 of the 8,365 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q2 2026, worth a combined $189M — up 441% from $34.9M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new NVCT positions and 6 closed out — a net gain of 22 holders — while 34 added to existing stakes and 11 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $17.4M. The largest seller was Occam Crest Management, cutting an estimated $560K.
- 82 institutional investors held Nuvectis Pharma (NVCT) as of Q2 2026, up from 62 in Q1 2026.
- Funds reported $189M of Nuvectis Pharma stock for Q2 2026, up 441% quarter-over-quarter.
- 28 funds opened new Nuvectis Pharma positions in Q2 2026 and 6 closed out, a net change of +22 holders.
- The largest Nuvectis Pharma buyer in Q2 2026 was Tang Capital Management, an estimated $17.4M added.
- The largest Nuvectis Pharma seller in Q2 2026 was Occam Crest Management, an estimated $560K sold.
Based on aggregated 13F filings for Q2 2026.